Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 4/20 | 0.66 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.66 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Losartan SCHEMBL7420948 | 1.00 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL4090171 | 1.00 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL6684517 | 0.99 | AGTR1 (0.65) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL6684460 | 0.99 | AGTR1 (0.65) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL28493004 | 0.99 | AGTR1 (0.65) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL60 | 0.99 | AGTR1 (0.67) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL29383742 | 0.99 | AGTR1 (0.67) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL6092394 | 0.99 | AGTR1 (0.67) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL4726128 | 0.98 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B | |
| Losartan SCHEMBL3216357 | 0.98 | AGTR1 (0.66) | AGTR1AGTR2ABCC4ABCB11PDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8016 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605365-B2 | Losartan liquid formulations and methods of use | SCIENTURE, LLC (US) | 2026-04-21 | — | — | US | claimed |
| US-20260060963-A1 | READY-TO-USE NON-AQUEOUS ORAL SOLUTION OF LOSARTAN | LIQMEDS WORLDWIDE LIMITED (GB) | 2026-03-05 | — | — | US | claimed |
| US-12496291-B1 | Ready-to-use non-aqueous oral solution of losartan | LIQMEDS WORLDWIDE LIMITED (GB) | 2025-12-16 | — | — | US | claimed |
| EP-4638742-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) | Shanghai Argo Biopharmaceutical Co., Ltd. (CN) | 2025-10-29 | — | — | EP | claimed |
| US-20250319070-A1 | LOSARTAN LIQUID FORMULATIONS AND METHODS OF USE | STREETERVILLE CAPITAL, LLC | 2025-10-16 | — | — | US | claimed |
| WO-2025131019-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF INHIBIN SUBUNIT BETA E (INHBE) | SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-06-26 | — | — | WO | claimed |
| CN-120044164-A | Method for detecting impurities in losartan potassium | 珠海润都制药股份有限公司 | 2025-05-27 | — | — | CN | claimed |
| WO-2025090879-A1 | PLURIPOTENT CELL DIFFERENTIATION | AMGEN INC. (US) | 2025-05-01 | — | — | WO | claimed |
| CN-119792218-A | Stable metaxartan potassium tablet and preparation method thereof | 江苏天士力帝益药业有限公司 | 2025-04-11 | — | — | CN | claimed |
| US-20250115584-A1 | High-Purity Losartan Potassium and Preparation Method Therefor | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2025-04-10 | — | — | US | claimed |
| WO-1998018787-A1 | PROCESS FOR THE CRYSTALLIZATION OF LOSARTAN | MERCK & CO., INC. (US) | 1998-05-07 | — | — | WO | claimed |
| EP-0831911-A2 | SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0831910-A1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0733366-B1 | Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics | DU PONT (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1997049392-A1 | A COMPOSITION OF ENALAPRIL AND LOSARTAN | MERCK & CO., INC. (US) | 1997-12-31 | — | — | WO | claimed |
| WO-1996040255-A2 | METHOD TO TREAT CARDIOFIBROSIS WITH A COMBINATION THERAPY OF AN ANGIOTENSIN II ANTAGONIST AND AN EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040257-A1 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040258-A2 | SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| WO-1996040256-A1 | METHOD TO TREAT CARDIOFIBROSIS WITH A COMBINATION OF AN ANGIOTENSIN II ANTAGONIST AND SPIRONOLACTONE | G.D. SEARLE & CO. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0733366-A2 | Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1996-09-25 | — | — | EP | claimed |